What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Pathology
Yves Boucher focuses on Pathology, Interstitial fluid, Cancer research, Blood flow and Angiogenesis.
Yves Boucher is involved in the study of Pathology that focuses on Lymphatic system in particular.
His research in Interstitial fluid intersects with topics in Docetaxel, Mammary gland, Blood pressure and Interstitial space.
His study in Cancer research is interdisciplinary in nature, drawing from both Hypoxia and Growth factor.
He focuses mostly in the field of Blood flow, narrowing it down to topics relating to Interstitial matrix and, in certain cases, Biophysics and Chemotherapy.
His Vascular endothelial growth factor research includes themes of Bevacizumab and Circulatory system.
His most cited work include:
- Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (1739 citations)
- Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors (953 citations)
- NORMALIZATION OF THE VASCULATURE FOR TREATMENT OF CANCER AND OTHER DISEASES (945 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Pathology, Cancer research, Interstitial fluid and Endocrinology.
His studies in Internal medicine integrate themes in fields like Neuropathic pain and Oncology.
Yves Boucher studies Lymphatic system which is a part of Pathology.
His Cancer research research incorporates elements of Cancer, Metastasis, Pancreatic cancer and Immunology.
He has included themes like Blood flow, Blood pressure, Oxygenation, Hemodynamics and Adenocarcinoma in his Interstitial fluid study.
His studies examine the connections between Bevacizumab and genetics, as well as such issues in Colorectal cancer, with regards to Vascular endothelial growth factor.
He most often published in these fields:
- Internal medicine (26.20%)
- Pathology (24.02%)
- Cancer research (17.47%)
What were the highlights of his more recent work (between 2016-2020)?
- Internal medicine (26.20%)
- Neuroinflammation (7.42%)
- Neuropathic pain (6.99%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Neuroinflammation, Neuropathic pain, Cancer research and Cancer.
The Internal medicine study combines topics in areas such as Orofacial pain, Endocrinology, Wnt signaling pathway and Gastroenterology.
His Cancer research research includes elements of Pancreatic cancer, Tumor microenvironment, Angiotensin receptor, Breast cancer and Angiotensin II receptor type 1.
His Cancer study integrates concerns from other disciplines, such as Extracellular matrix, T lymphocyte, Proportional hazards model and Oncology.
His work in Cyclopamine is not limited to one particular discipline; it also encompasses Pathology.
His specific area of interest is Pathology, where Yves Boucher studies Carcinoma.
Between 2016 and 2020, his most popular works were:
- Solid stress and elastic energy as measures of tumour mechanopathology (138 citations)
- Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. (116 citations)
- Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. (70 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Pathology
His main research concerns Cancer research, FOLFIRINOX, Capecitabine, Downregulation and upregulation and Chemotherapy.
The study incorporates disciplines such as T lymphocyte, Myofibroblast, Tumor microenvironment, Renin–angiotensin system and Breast cancer in addition to Cancer research.
His Capecitabine study combines topics in areas such as Surgery and Pancreatic cancer.
In his study, which falls under the umbrella issue of Downregulation and upregulation, Pathology is strongly linked to Cyclopamine.
His study in Pathology focuses on Vascular permeability in particular.
His Chemotherapy research is multidisciplinary, incorporating perspectives in Carcinoma, Lisinopril, Wnt signaling pathway and Adenocarcinoma.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
